{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:07:45Z","timestamp":1778771265750,"version":"3.51.4"},"reference-count":135,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CCDT"],"published-print":{"date-parts":[[2018,12,13]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Nonsteroidal anti-inflammatory drugs (NSAIDs) and particularly selective cyclooxygenase-2 (COX-2) inhibitors such as celecoxib (Cxb) are considered promising cancer chemopreventive for colon, breast, prostate, lung, and skin cancers. However, the clinical application to the prevention is limited by concerns about safety, potential to serious toxicity (mainly for healthy individuals), efficacy and optimal treatment regimen. Cxb exhibits advantages as potent antiinflammatory and gastrointestinal tolerance compared with conventional NSAID\u2019s. Recent researches suggest that dermatological formulations of Cxb are more suitable than oral administration in the treatment of cutaneous disease, including skin cancer. To date, optimism has been growing regarding the exploration of the topical application of Cxb (in the prevention of skin cancers and treatment of cutaneous inflammation) or transdermal route reducing risks of systemic side effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>This paper briefly summarizes our current knowledge of the development of the cutaneous formulations or delivery systems for Cxb as anti-inflammatory drug (for topical or transdermal application) as well its chemopreventive properties focused on skin cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title\/><jats:p>New perspectives emerge from the growing knowledge, bringing innovative techniques combining the action of Cxb with other substances or agents which act in a different way, but complementary, increasing the efficacy and minimizing toxicity.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1568009618666180430125201","type":"journal-article","created":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T11:36:47Z","timestamp":1525174607000},"page":"5-16","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Cutaneous Application of Celecoxib for Inflammatory and Cancer Diseases"],"prefix":"10.2174","volume":"19","author":[{"given":"Oliesia Gonzalez","family":"Qui\u00f1ones","sequence":"first","affiliation":[{"name":"School of Pharmacy, Federal University of Rio de Janeiro, Av. Carlos Chagas Filho 373, 21.941.902, Rio de Janeiro, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Bernadete Riemma","family":"Pierre","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Federal University of Rio de Janeiro, Av. Carlos Chagas Filho 373, 21.941.902, Rio de Janeiro, RJ, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","author":"Hilal-Dandan R.","unstructured":"Hilal-Dandan R, Brunton L, , Mc Graw Hill Education,, , 2nd ed, Goodman and Gilman\u2019s Manual of Pharmacology and Therapeutics., 2014,879-913","journal-title":"Goodman and Gilman\u2019s Manual of Pharmacology and Therapeutics"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000318746","volume":"83","author":"Sakamoto C.","year":"2011","unstructured":"Sakamoto C, Soen S. Digestion, Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in japan.,, 2011, 83,, 108-123,","journal-title":"Digestion"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1007\/s00535-012-0717-6","volume":"48","author":"Jarupongprapa S.","year":"2013","unstructured":"Jarupongprapa S, Ussavasodhi P, Katchamart W. J Gastroenterol, Comparison of gastrointestinal adverse effects between cyclooxygenase-2 inhibitors and non- selective, non-steroidal anti-inflammatory drugs plus proton pump inhibitors: a systemic review and meta-analysis.,, 2013, 48,, 830-838,","journal-title":"J Gastroenterol"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0168-3659(03)00200-1","volume":"90","author":"Chauhan A.S.","year":"2003","unstructured":"Chauhan AS, Sridevi S, Chalsani KB, Jain AK, Jain SK, Jain NK, Diwan PV. J Control Release, Dendrimer-mediated transdermal delivery: enhanced bioavailability of indomethacin.,, 2003, 90,, 335-343,","journal-title":"J Control Release"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S0006-2952(00)00576-1","volume":"61","author":"Lichtenberger L.M.","year":"2001","unstructured":"Lichtenberger LM. Biochem Pharmacol, Where is the evidence that cyclooxigenase inhibition is the primary cause of nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited.,, 2001, 61,, 631-637,","journal-title":"Biochem Pharmacol"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1158\/1940-6207.CAPR-11-0166","volume":"4","author":"Fischer S.M.","year":"2011","unstructured":"Fischer SM, Hawk ET, Lubet RA. Cancer Prev Res (Phila), Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention.,, 2011, 4,, 1728-1735,","journal-title":"Cancer Prev Res (Phila)"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ejpb.2011.08.002","volume":"80","author":"Mennini N.","year":"2011","unstructured":"Mennini N, Furlanetto S, Cirri M, Mura P. Eur J Pharm Biopharm, Quality by design approach for developing chitosan-Ca-alginate microspheres for colon delivery of celecoxib-hydroxypropyl-\u03b2-cyclodextrin-PVP complex.,, 2011, 80,, 67-75,","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ijpharm.2010.04.012","volume":"393","author":"Margulis-Goshen K.","year":"2010","unstructured":"Margulis-Goshen K, Kesselman E, Danino D, Magdassi S. Int J Pharm, Formation of celecoxib nanoparticles from volatile microemulsions.,, 2010, 393,, 230-237,","journal-title":"Int J Pharm"},{"key":"ref=9","first-page":"459","volume":"4","author":"Soliman S.M.","year":"2010","unstructured":"Soliman SM, Abdel-Malak NS, El-Gazayerley ON, Abdel Rehim AA. Drug Discov Ther, Formulation of microemulsion gel systems for transdermal delivery of celecoxib: In vitro permeation, anti-inflammatory activity and skin irritation test.,, 2010, 4,, 459-471,","journal-title":"Drug Discov Ther"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/10611860802473402","volume":"16","author":"Shakeel F.","year":"2008","unstructured":"Shakeel F, Baboota S, Ahuja A, Ali J, Shafiq S. J Drug Target, Celecoxib nanoemulsion: Skin permeation mechanism and biovailability assesment.,, 2008, 16,, 733-740,","journal-title":"J Drug Target"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1477-3155-6-8","volume":"6","author":"Shakeel F.","year":"2008","unstructured":"Shakeel F, Baboota S, Ahuja A, Ali J, Shafiq S. J Nanobiotechnology, Skin permeation mechanism and bioavailability enhancement of celecoxib from transdermally applied nanoemulsion.,, 2008, 6,, 8-,","journal-title":"J Nanobiotechnology"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jcis.2006.01.060","volume":"299","author":"Garti N.","year":"2009","unstructured":"Garti N, Avrahami M, Aserin A. J Colloid Interface Sci, Improved solubilization of celecoxib in U-type nonionic microemulsions and their structural transitions with progressive aqueous dilution.,, 2009, 299,, 352-365,","journal-title":"J Colloid Interface Sci"},{"key":"ref=13","first-page":"335","volume":"61","author":"Subramanian N.","year":"2004","unstructured":"Subramanian N, Ghosal SK, Moulik SP. Acta Pol Pharm, Topical delivery of celecoxib using microemulsion.,, 2004, 61,, 335-341,","journal-title":"Acta Pol Pharm"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"4390","DOI":"10.1002\/jps.22623","volume":"100","author":"","year":"2011","unstructured":". J Pharm Sci, Weitman, M.; Major, D.T.; Magdassi, S. Inhibition of crystallization and growth of celecoxib nanoparticles formed from volatile microemulsions.,Margulis-Goshen, 2011, 100,, 4390-4400,","journal-title":"J Pharm Sci"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1042\/BSR20090104","volume":"30","author":"Deniz A.","year":"2010","unstructured":"Deniz A, Sade A, Severcan F, Keskin D, Tezcaner A, Banerjee S. Biosci Rep, Celecoxib-loaded liposomes: effect of cholesterol on encapsulation and in vitro release characteristics.,, 2010, 30,, 365-373,","journal-title":"Biosci Rep"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1208\/s12249-009-9364-5","volume":"11","author":"Nasr M.","year":"2010","unstructured":"Nasr M. AAPS PharmSciTech, In vitro and in vivo evaluation of proniosomes containing celecoxib for oral adminitration.,, 2010, 11,, 85-89,","journal-title":"AAPS PharmSciTech"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0090-9556(24)15366-4","volume":"28","author":"Paulson S.K.","year":"2000","unstructured":"Paulson SK, Hribar JD, Liu NW, Hajdu E, Bible RH, Piergies A, Karim A. Drug Metab Dispos, Metabolism and excretion of [14C]celecoxib in healthy male volunteers.,, 2000, 28,, 308-314,","journal-title":"Drug Metab Dispos"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1021\/mp2005164","volume":"9","author":"Malik P.","year":"2012","unstructured":"Malik P, Kadam RS, Cheruvu NP, Kompella UB. Mol Pharm, Hidrophilic produg approach for reduced pigment binding and enhanced transscleral retinal delivery of celecoxib.,, 2012, 9,, 605-614,","journal-title":"Mol Pharm"},{"key":"ref=19","first-page":"330","volume":"58","author":"Yener G.","year":"2003","unstructured":"Yener G, G\u00f6n\u00fcll\u00fc U, Uner M, De\u011fim T, Araman A. Pharmazie, Effects of vehicles and penetration enhancers on the in vitro percutaneous absorption of celecoxib through human skin.,, 2003, 58,, 330-333,","journal-title":"Pharmazie"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jconrel.2012.01.004","volume":"160","author":"Bachar M.","year":"2012","unstructured":"Bachar M, Mandelbaum A, Portnaya I, Perlstein H, Even-Chen S, Barenholz Y, Danino D. J Control Release, Development and characterization of a novel drug nanocarrier for oral delivery, based on self-assembled \u03b2-casein micelles.,, 2012, 160,, 164-171,","journal-title":"J Control Release"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/03639040500214605","volume":"31","author":"Subramanian N.","year":"2005","unstructured":"Subramanian N, Ghosal SK, Moulik SP. Drug Dev Ind Pharm, Enhanced in vitro percutaneous absorption and in vivo anti-inflamatory effect of a selective cyclooxygenase inhibitor using microemulsion.,, 2005, 31,, 405-416,","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00126839-200708050-00002","volume":"8","author":"Thakkar H.","year":"2007","unstructured":"Thakkar H, Kumar-Sharma R, Murthy RS. Drugs R D, Enhanced retention of celecoxib-loaded solid lipid nanoparticles after intra-articular administration.,, 2007, 8,, 275-285,","journal-title":"Drugs R D"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2174\/1568009043481632","volume":"4","author":"Rao C.V.","year":"2004","unstructured":"Rao CV, Reddy BS. Curr Cancer Drug Targets, NSAIDs and Chemoprevention.,, 2004, 4,, 29-42,","journal-title":"Curr Cancer Drug Targets"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1526-4637.2010.00809.x","volume":"11","author":"Haroutiunian S.","year":"2010","unstructured":"Haroutiunian S, Drennan DA, Lipman GA. Pain Med, Topical NSAID therapy for musculoskeletal pain.,, 2010, 11,, 535-549,","journal-title":"Pain Med"},{"key":"ref=25","author":"","unstructured":"Okyar, A.; Ozsoy, Y.; Gungor, S. Novel formulation approaches for dermal and transdermal delivery of non-steroidal antiinflammatory drugs, rheumatoid arthritis - treatment, intech, 2012; available from, . http:\/\/www.intechopen.com\/books\/rheumatoid-arthritis-treatment\/novel-formulation-approaches-for-dermaland-transdermal-delivery-of-non-steroidal-anti-inflammatory, , ,"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"803","DOI":"10.4103\/ijmr.IJMR_626_16","volume":"144","author":"Loh T.Y.","year":"2016","unstructured":"Loh TY, Cohen PR. Indian J Med Res, Ketoprofen-induced photoallergic dermatitis.,, 2016, 144,, 803-806,","journal-title":"Indian J Med Res"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.bpg.2011.10.012","volume":"25","author":"Wu X.","year":"2011","unstructured":"Wu X, Patterson S, Hawk E. Best Pract Res Clin Gastroenterol, Chemoprevention-history and general principles.,, 2011, 25,, 445-459,","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1002\/ijc.26286","volume":"130","author":"Cahoon E.K.","year":"2012","unstructured":"Cahoon EK, Rajaraman P, Alexander BH, Doody MM, Linet MS, Freedman DM. Int J Cancer, Use of nonesteroidal anti-inflammatory drugs and risk of basal cell carcinoma in the united states radiologic technologist study.,, 2012, 130,, 2939-2948,","journal-title":"Int J Cancer"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.2174\/138945011795677764","volume":"12","author":"Khan Z.","year":"2011","unstructured":"Khan Z, Khan N, Tiwari RP, Sah NK, Prasad GB, Bisen PS. Curr Drug Targets, Biology of COX-2: An application in cancer therapeutics.,, 2011, 12,, 1082-1093,","journal-title":"Curr Drug Targets"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.2147\/IJN.S19497","volume":"6","author":"Kim T.H.","year":"2011","unstructured":"Kim TH, Jeong YI, Jin SG, Pei J, Jung TY, Moon KS, Kim IY, Kang SS, Jung S. Int J Nanomedicine, Preparation of polylactide-co-glycolide nanoparticles incorparating celecoxib and their antitumor activity against brain tumor cells.,, 2011, 6,, 2621-2631,","journal-title":"Int J Nanomedicine"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/10837450.2012.751403","volume":"19","author":"Shamsher A.A.","year":"2014","unstructured":"Shamsher AA, Charoo NA, Rahman Z, Pillai KK, Kohli K. Pharm Dev Technol, Tulsi oil as a potencial penetration enhancer for celecoxib transdermal gel formulations.,, 2014, 19,, 21-30,","journal-title":"Pharm Dev Technol"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ejps.2012.01.003","volume":"45","author":"Zhao P.","year":"2012","unstructured":"Zhao P, Jiang H, Jiang T, Zhi Z, Wu C, Sun C, Zhang J, Wang S. Eur J Pharm Sci, Inclusion of celecoxib into fibrous ordered mesoporous carbon for enhanced oral bioavailability and reduced gastric irritancy.,, 2012, 45,, 639-647,","journal-title":"Eur J Pharm Sci"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s11095-012-0943-x","volume":"30","author":"Wan F.","year":"2013","unstructured":"Wan F, Bohr A, Maltesen MJ, Bjerregaard S, Foged C, Rantanen J, Yang M. Pharm Res, Critical solvent properties affecting the particle formation process and characteristics of celecoxib-loaded PLGA microparticles via spray-drying.,, 2013, 30,, 1065-1076,","journal-title":"Pharm Res"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1021\/mp200157b","volume":"8","author":"Abu-Diak O.A.","year":"2011","unstructured":"Abu-Diak OA, Jones DS, Andrews GP. Mol Pharm, An investigation into the dissolution properties of celecoxib melt extrudates: understanding the role of polymer type and concentration in stabilizing supersaturated drug concentrations.,, 2011, 8,, 1362-,","journal-title":"Mol Pharm"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"4147","DOI":"10.1016\/j.bmcl.2010.05.054","volume":"20","author":"Cheng S.Y.","year":"2010","unstructured":"Cheng SY, Yuen MC, Lam PL, Gambari R, Wong RS, Cheng GY, Lia PB, Tong SW, Chan KW, Lau FY, Kok SH, Lam KH, Chui CH. Bioorg Med Chem Lett, Synthesis, characterization and preliminary analysis of in vivo biological activity of chitosan\/celecoxib micropsules.,, 2010, 20,, 4147-4151,","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1208\/s12249-013-9957-x","volume":"14","author":"Nasr M.","year":"2013","unstructured":"Nasr M. AAPS PharmSciTech, Influence of microcrystal formulation on in vivo absorption of celecoxib in rats.,, 2013, 14,, 719-726,","journal-title":"AAPS PharmSciTech"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jconrel.2010.02.006","volume":"144","author":"Patlolla R.R.","year":"2010","unstructured":"Patlolla RR, Chougule M, Patel AR, Jackson T, Tata PN, Singh M. J Control Release, Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers.,, 2010, 144,, 233-241,","journal-title":"J Control Release"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/jps.23417","volume":"102","author":"Ibrahim M.M.","year":"2013","unstructured":"Ibrahim MM, Abd-Elgawad AE, Soliman OA, Jablonski MM. J Pharm Sci, Nanoparticle-based topical ophthalmic formulations for sustained celecoxib release.,, 2013, 102,, 1036-1053,","journal-title":"J Pharm Sci"},{"key":"ref=39","first-page":"150","volume":"14","author":"Amrite A.C.","year":"2008","unstructured":"Amrite AC, Edelhauser HF, Singh SR, Kompella UB. Mol Vis, Effect of circulation on the disposition and ocular tissue distribution of 20 nm nanoparticles after periocular administration.,, 2008, 14,, 150-160,","journal-title":"Mol Vis"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"246","DOI":"10.4103\/0973-8398.45040","volume":"2","author":"Thakkar H.P.","year":"2008","unstructured":"Thakkar HP, Murthy RR. Asian J Pharm, Effect of cross-linking on the characteristics of the celecoxib loaded chitosan microspheres.,, 2008, 2,, 246-251,","journal-title":"Asian J Pharm"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3109\/03639045.2013.809731","volume":"40","author":"Qui\u00f1ones O.G.","year":"2014","unstructured":"Qui\u00f1ones OG, Mata dos Santos HA, Kibwila DM, Leit\u00e3o A, dos Santos Pyrrho A, P\u00e1dula M, Rosas EC, Lara MG, Pierre MBR. Drug Dev Ind Pharm, In vitro and in vivo influence of penetration enhancers in the topical application of celecoxib.,, 2014, 40,, 1180-1189,","journal-title":"Drug Dev Ind Pharm"},{"key":"ref=42","first-page":"67","volume":"53","author":"Sharma R.","year":"2011","unstructured":"Sharma R, Mehra GR. Acta Pharm Sci, Preparation, characterization, in vitro and in vivo evaluation of transdermal matrix films of celecoxib.,, 2011, 53,, 67-76,","journal-title":"Acta Pharm Sci"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2306\/scienceasia1513-1874.2010.36.305","volume":"36","author":"Alam M.I.","year":"2010","unstructured":"Alam MI, Baboota S, Kohli K, Ali J, Ahuja A. Sci Asia, Pharmacodymanic evaluation of proniosomal transdermal therapeutic gel containing celecoxib.,, 2010, 36,, 305-311,","journal-title":"Sci Asia"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijpharm.2007.05.060","volume":"346","author":"Joshi M.","year":"2008","unstructured":"Joshi M, Patravale V. Int J Pharm, Nanostructured lipid carrier (NLC) based gel of celecoxib.,, 2008, 346,, 124-132,","journal-title":"Int J Pharm"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2478\/v10007-007-0025-5","volume":"57","author":"Baboota S.","year":"2007","unstructured":"Baboota S, Shakeel F, Ahuja A, Ali J, Shafiq S. Acta Pharm, Design, devolepment and evaluation of novel nanoemulsion formulations for transdermal potencial of celecoxib.,, 2007, 57,, 315-332,","journal-title":"Acta Pharm"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1007\/s11095-012-0789-2","volume":"29","author":"Desai P.R.","year":"2012","unstructured":"Desai PR, Shah PP, Patlolla RR, Singh M. Pharm Res, Dermal microdialysis technique to evaluate the trafficking of surface-modified lipid nanoparticles upon topical application.,, 2012, 29,, 2587-2600,","journal-title":"Pharm Res"},{"key":"ref=47","first-page":"2216","volume":"4","author":"Sharma P.K.","year":"2011","unstructured":"Sharma PK, Bajpai M. J Pharm Res, Enhancement of solubility and stability of celecoxib using microemulsion based topical formulation.,, 2011, 4,, 2216-2220,","journal-title":"J Pharm Res"},{"key":"ref=48","first-page":"1609","volume":"3","author":"Begum M.Y.","year":"2011","unstructured":"Begum MY, Abbulu K, Sudhakar M, Jayaprakash S. Int J Pharm Tech Res, Studies on the development of celecoxib transdermal patches.,, 2011, 3,, 1609-1615,","journal-title":"Int J Pharm Tech Res"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1208\/s12249-010-9420-1","volume":"11","author":"Moreira T.S.","year":"2010","unstructured":"Moreira TS, de Sousa VP, Pierre MBR. AAPS PharmSciTech, A novel transdermal delivery system for the anti\u2013inflamatory Lumiracoxib: Influence of Oleic Acid on in vitro percutaneous absorption and in vivo potencial cutaneous irritation.,, 2010, 11,, 621-629,","journal-title":"AAPS PharmSciTech"},{"key":"ref=50","author":"Gibson M.","unstructured":"Gibson M, , Drugs and the Pharmaceuticals Sciences,, , 2nd ed, Pharmaceutical Preformulation and Formulation: A Practical Guide from Candidate Drug Selection to Comercial Dosage Form. Volume 199., 2009,-","journal-title":"Pharmaceutical Preformulation and Formulation: A Practical Guide from Candidate Drug Selection to Comercial Dosage Form Volume 199"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.chemphyslip.2013.07.010","volume":"176","author":"Khurana S.","year":"2013","unstructured":"Khurana S, Bedi PM, Jain NK. Chem Phys Lipids, Preparation and evaluation of solid lipid nanoparticles based nanogel for dermal delivery of meloxicam.,, 2013, 176,, 65-72,","journal-title":"Chem Phys Lipids"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejpb.2010.12.010","volume":"78","author":"Manconi M.","year":"2011","unstructured":"Manconi M, Caddeo C, Sinico C, Valenti D, Mostallino MC, Biggio G, Fadda AM. Eur J Pharm Biopharm, Ex vivo skin delivery of diclofenac by transcutol containing liposomes.,, 2011, 78,, 27-35,","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ijpharm.2006.10.041","volume":"335","author":"Nokhodchi A.","year":"2007","unstructured":"Nokhodchi A, Sharabiani K, Rashidi MR, Ghafourian T. Int J Pharm, The effect of terpene concentrations on the skin penetration of diclofenac sodium.,, 2007, 335,, 97-105,","journal-title":"Int J Pharm"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ddr.21179","volume":"75","author":"Fetih G.","year":"2014","unstructured":"Fetih G, Fathalla D, El-Badry M. Drug Dev Res, Liposomal gels for site-specific, sustained delivery of celecoxib: in vitro and in vivo evaluation.,, 2014, 75,, 257-266,","journal-title":"Drug Dev Res"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1016\/j.biomaterials.2011.01.027","volume":"32","author":"Venkatesan P.","year":"2011","unstructured":"Venkatesan P, Puwada N, Dash R, Prashanth Kumar BN, Sarkar D, Azab B, Pathak A, Kundu SC, Fisher PB, Mandal M. Biomaterials, The potential of celecoxib-loaded hydroxyapatite-chitosan nanocomposite for the treatment of colon cancer.,, 2011, 32,, 3794-3806,","journal-title":"Biomaterials"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.bcp.2007.09.005","volume":"75","author":"Bijman M.N.","year":"2008","unstructured":"Bijman MN, Hermelink CA, van Berkel PA, Laan AC, Janmaat ML, Peters GJ, Boven E. Biochem Pharmacol, Interaction between celecoxib and docetaxel or cisplatin in human cell lines of ovarian cancer and colon cancer is independent of COX-2 expression levels.,, 2008, 75,, 427-437,","journal-title":"Biochem Pharmacol"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJM200006293422603","volume":"342","author":"Steinbach G.","year":"2000","unstructured":"Steinbach G, Lynch PM, Phillips RK, Wallace MH, Hawk E, Gordon GB, Wakabayashi N, Saunders B, Shen Y, Fujimura T, Su LK, Levin B, Godio L, Patterson S, Rodriguez-Bigas MA, Jester SL, King KL, Schumacher M, Abbruzzese J, DuBois RN, Hittelman WN, Zimmerman S, Sherman JW, Kelloff G. N Engl J Med, The effect of celecoxib, a cyclooxigenase\u20132 inhibitors, in familial adenomatous polyposis.,, 2000, 342,, 1946-1952,","journal-title":"N Engl J Med"},{"key":"ref=58","first-page":"409","volume":"58","author":"Kawamori T.","year":"1998","unstructured":"Kawamori T, Rao CV, Seibert K, Reddy BS. Cancer Res, Chemopreventive activity of celecoxib, a especific cyclooxygenase-2 inhibitor, against colon carcinogenesis.,, 1998, 58,, 409-412,","journal-title":"Cancer Res"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1158\/1940-6207.CAPR-13-0215","volume":"7","author":"Saba N.F.","year":"2014","unstructured":"Saba NF, Hurwitz SJ, Kono SA, Yang CS, Zhao Y, Chen Z, Sica G, M\u00fcller S, Moreno-Williams R, Lewis M, Grist W, Chen AY, Moore CE, Owonikoko TK, Ramalingam S, Beitler JJ, Nannapaneni S, Shin HJ, Grandis JR, Khuri FR, Chen ZG, Shin DM. Cancer Prev Res (Phila), Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study.,, 2014, 7,, 283-291,","journal-title":"Cancer Prev Res (Phila)"},{"key":"ref=60","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/jop.12081","volume":"42","author":"Abrah\u00e3o A.C.","year":"2013","unstructured":"Abrah\u00e3o AC, Giudice FS, Sperandio FF, Pinto Junior Ddos S. J Oral Pathol Med, Effects of celecoxib treatment over the AKT pathway in head and neck squamous cell carcinoma.,, 2013, 42,, 793-798,","journal-title":"J Oral Pathol Med"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jss.2008.05.022","volume":"154","author":"Kilic A.","year":"2009","unstructured":"Kilic A, Schuchert MJ, Luketich JD, Landreneau RJ, El-Hefnawy T. J Surg Res, Efficacy of signal pathway inhibitors alone and combination with cisplatin varies between human non\u2013small cell lung cancer lines.,, 2009, 154,, 9-12,","journal-title":"J Surg Res"},{"key":"ref=62","first-page":"245","volume":"66","author":"Okada T.","year":"2012","unstructured":"Okada T, Takigawa N, Kishino D, Katayama H, Kuyama S, Sato K, Mimoto J, Ueoka H, Tanimoto M, Kiura K. Acta Med Okayama, Selective cyclooxigenase-2 inhibitor prevents cisplatin-induced tmorigenesis in A\/J Mice.,, 2012, 66,, 245-251,","journal-title":"Acta Med Okayama"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1158\/1078-0432.CCR-06-0474","volume":"12","author":"Buckstein R.","year":"2006","unstructured":"Buckstein R, Kerbel RS, Shaked Y, Nayar R, Foden C, Turner R, Lee CR, Taylor D, Zhang L, Man S, Baruchel S, Stempak D, Bertolini F, Crump M. Clin Cancer Res, High-dose celecoxib and metro- nomic \u201cLow-dose\u201d cyclophosphamide is an effective and safe therapy in patients with relapse and refractory agressive histology Non-Hodgkins lymphoma.,, 2006, 12,, 5190-5198,","journal-title":"Clin Cancer Res"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1749-6632.2009.04888.x","volume":"1171","author":"Kim S.H.","year":"2009","unstructured":"Kim SH, Kim SH, Song YC, Song YS. Ann N Y Acad Sci, Celecoxib potentiates the anticancer effects of cisplastin on vulvar cancer cells independently of cyclooxigenase.,, 2009, 1171,, 635-641,","journal-title":"Ann N Y Acad Sci"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10616-010-9296-7","volume":"62","author":"Chen J.","year":"2010","unstructured":"Chen J, Ran Y, Hong C, Chen Z, You Y. Cytotchenology, Anti-cancer effects of celecoxib on nasopharyngeal carcinoma HNE-1 cells expression COX-2 oncoprotein.,, 2010, 62,, 431-438,","journal-title":"Cytotchenology"},{"key":"ref=66","first-page":"579","volume":"39","author":"Li W.Z.","year":"2010","unstructured":"Li WZ, Wang XY, Li ZG, Zhang JH, Ding YQ. J Oral Pathol Med, Celecoxib enhances the inhibitory effect of cispalstin on Tca8113 cells in human tongue squamous cell carcinoma in vivo and in vitro.,, 2010, 39,, 579-584,","journal-title":"J Oral Pathol Med"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/mol.110.069393","volume":"79","author":"Yu L.","year":"2011","unstructured":"Yu L, Chen M, Li Z, Wen J, Fu J, Guo D, Jiang Y, Wu S, Cho CH, Liu S. Mol Pharmacol, Celecoxib antagonizes the cytotoxicity of cisplatin in human esophageal squamous cell carcinoma by reducing intracellular cisplatin accumulation.,, 2011, 79,, 608-617,","journal-title":"Mol Pharmacol"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"442","DOI":"10.4103\/0973-1482.92013","volume":"7","author":"Mohammadianpanah M.","year":"2011","unstructured":"Mohammadianpanah M, Razmjou-Ghalaei S, Shafizad A, Ashouri-Taziani Y, Khademi B, Ahmadloo N, Ansari M, Omidvari S, Mosalaei A, Mosleh-Shirazi MA. J Cancer Res Ther, Efficacy and safety of current chemoradiation with weekly cisplatin \u00b1 low\u2013dose celecoxib in locally advanced un- differentiated nasopharygeal carcinoma: A phase II\u2013III clinical trial.,, 2011, 7,, 442-447,","journal-title":"J Cancer Res Ther"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.amjoto.2010.11.010","volume":"32","author":"Cohen S.","year":"","unstructured":"Cohen S, Efraim AN, Levi-Schaffer F, Eliashar R. Am J Otolaryngol, The effect of hypoxia and cyclooxigenase inhibitors on nasal polyp derived fibroblasts.,, , 32,, 564-573,2011","journal-title":"Am J Otolaryngol"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"e33615","DOI":"10.1371\/journal.pone.0033615","volume":"7","author":"Huang K.H.","year":"2012","unstructured":"Huang KH, Kuo KL, Chen SC, Weng TI, Chuang YT, Tsai YC, Pu YS, Chiang CK, Liu SH. PLoS One, Down\u2013regulation of glucose\u2013regulated protein (GRP) 78 potentiates cytotoxic effects of celecoxib in human urothelial carcinoma cells.,, 2012, 7,, e33615-,","journal-title":"PLoS One"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11060-011-0662-x","volume":"106","author":"Sareddy G.R.","year":"2012","unstructured":"Sareddy GR, Geeviman K, Ramulu C, Babu PP. J Neurooncol, The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-\u03baB pathway.,, 2012, 106,, 99-109,","journal-title":"J Neurooncol"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"S293","DOI":"10.1016\/S0753-3322(05)80049-6","volume":"59","author":"Chiu L.C.","year":"2005","unstructured":"Chiu LC, Tong KF, Ooi VE. Biomed Pharmacother, Cytostatic and cytotoxic effects of cyclooxigenase inhbitors and their synergy with docosahexaenoic acid on the growth of human skin melanoma A-375 cells.,, 2005, 59,, S293-S297,","journal-title":"Biomed Pharmacother"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1093\/annonc\/mdl311","volume":"17","author":"Gogas H.","year":"2006","unstructured":"Gogas H, Polyzos A, Stavrinidis I, Frangia K, Tsoutsos D, Panagiotou P, Markopoulos C, Papadopoulos O, Pectasides D, Mantzourani M, Middleton M, Vaiopoulos G, Fountzilas G. Ann Oncol, Temozolomide in combination with celecoxib in patients with advanced melanoma. a phase ii study of the Hellenic Cooperative Oncology Group.,, 2006, 17,, 1835-1841,","journal-title":"Ann Oncol"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/1476-4598-12-47","volume":"12","author":"Pagliarulo V.","year":"2013","unstructured":"Pagliarulo V, Ancona P, Niso M, Colabufo NA, Contino M, Cormio L, Azzariti A, Pagliarulo A. Mol Cancer, The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line.,, 2013, 12,, 47-,","journal-title":"Mol Cancer"},{"key":"ref=75","first-page":"2173","volume":"8","author":"Kim C.H.","year":"2013","unstructured":"Kim CH, Chung CW, Lee HM. Int J Nanomedicine, Kim do, H.; Kwak, T.W.; Jeong, Y.I.; Kang, D.H. Synergistic effects of 5-aminolevulinic acid based photodynamic therapy and celecoxib via oxidative stress in human cholangiocarcinoma cells.,, 2013, 8,, 2173-2186,","journal-title":"Int J Nanomedicine"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.yexcr.2013.03.012","volume":"319","author":"Song J.","year":"2013","unstructured":"Song J, Chen Q, Xing D. Exp Cell Res, Enhanced apoptotic effects by downregulating Mcl-1: Evidence for the improvement of photodynamic therapy with Celecoxib.,, 2013, 319,, 1491-1504,","journal-title":"Exp Cell Res"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.febslet.2013.01.041","volume":"587","author":"Hyter S.","year":"2013","unstructured":"Hyter S, Indra AK. FEBS Lett, Nuclear hormone receptor functions in keratinocyte and melanocyte homeostasis, epidermal carcinogenesis and melanomagenesis.,, 2013, 587,, 529-541,","journal-title":"FEBS Lett"},{"key":"ref=78","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0041-008X(03)00301-6","volume":"192","author":"Lee J.L.","year":"2003","unstructured":"Lee JL, Mukhtar H, Bickers DR, Kopelovich L, Athar M. Toxicol Appl Pharmacol, Cyclooxygenase in the skin: pharmacological and toxicological implications.,, 2003, 192,, 294-306,","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/sj.jid.5700746","volume":"127","author":"Hatton J.L.","year":"2007","unstructured":"Hatton JL, Parent A, Tober KL, Hoppes T, Wulff BC, Duncan FJ, Kusewitt DF, VanBuskirk AM, Oberyszyn TM. J Invest Dermatol, Depletion of CD4+ cells exacerbates the cutaneous response to acute and chronic UVB exposure.,, 2007, 127,, 1507-1515,","journal-title":"J Invest Dermatol"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/mc.10141","volume":"38","author":"Wilgus T.A.","year":"2003","unstructured":"Wilgus TA, Koki AT, Zweifel BS, Kusewitt DF, Rubal PA, Oberyszyn TM. Mol Carcinog, Inhbition of cutaneous ultraviolet light B\u2013mediated inflamation and tumor formation with topical celecoxib treatment.,, 2003, 38,, 49-58,","journal-title":"Mol Carcinog"},{"key":"ref=81","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00403-011-1194-0","volume":"304","author":"Coco\u015f R.","year":"2012","unstructured":"Coco\u015f R, Schipor S, Nicolae I, Thomescu C, Raicu F. Arch Dermatol Res, Role of COX-2 activity and CRP levels in patients with non\u2013melanoma skin cancer. \u2013765GC PTGS2 polymorphism and NMSC risk.,, 2012, 304,, 335-342,","journal-title":"Arch Dermatol Res"},{"key":"ref=82","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/mc.20728","volume":"5D","author":"Chun K.S.","year":"2011","unstructured":"Chun KS, Langenbach R. Mol Carcinog, The prostaglandin E2 receptor, EP2, regulates survivin expression via an EGFR\/STAT3 pathway in UVB-exposed mouse skin.,, 2011, 5D,, 439-448,","journal-title":"Mol Carcinog"},{"key":"ref=83","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/carcin\/19.5.723","volume":"19","author":"Buckman S.Y.","year":"1998","unstructured":"Buckman SY, Gresham A, Hale P, Hruza G, Anast J, Masferrer J, Pentland AP. Carcinogenesis, COX-2 expression is induced by UVB exposure in human skin: Implications for the development of skin cancer.,, 1998, 19,, 723-729,","journal-title":"Carcinogenesis"},{"key":"ref=84","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/sj.jid.5700014","volume":"126","author":"Tober K.L.","year":"2006","unstructured":"Tober KL, Wilgus TA, Kusewitt DF. J Invest Dermatol, Thomas-Ahner, J.M.; Maruyama, T.; Oberyszyn, T.M. Importance of the EP1 receptor in cutaneuos UVB\u2013Induced inflamation and tumor development.,, 2006, 126,, 205-211,","journal-title":"J Invest Dermatol"},{"key":"ref=85","doi-asserted-by":"crossref","first-page":"e25224","DOI":"10.1371\/journal.pone.0025224","volume":"6","author":"Singh T.","year":"2011","unstructured":"Singh T, Katiyar SK. PLoS One, Green tea catechins reduce invasive potencial of human melanoma cells by targeting COX-2, PGE2 Receptors and Epithelial to Mesenchymal Transition.,, 2011, 6,, e25224-,","journal-title":"PLoS One"},{"key":"ref=86","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/carcin\/bgq215","volume":"32","author":"Singh T.","year":"2011","unstructured":"Singh T, Vaid M, Katiyar N, Sharma S, Katiyar SK. Carcinogenesis, Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the espressions of cyclooxygenase-2, prostaglandin E2 and prostaglandin E2 receptors.,, 2011, 32,, 86-92,","journal-title":"Carcinogenesis"},{"key":"ref=87","author":"Maglio D.H.G.","unstructured":"Cyclooxygenase-2 overexpression in non-melanoma skin cancer: molecular pathways involved as targets for prevention and treatment. skin cancers - risk factors, prevention and therapy, 2011, Prof. Caterina La Porta (Ed.), ISBN: 978- 953-307-722-2, InTech, Available from:, Maglio DHG, Paz ML, Cela EM, Leoni J. http:\/\/www.intechopen.com\/books\/skin-cancers-risk-factorsprevention-and-therapy\/cyclooxygenase-2-overexpression-in-non-melanoma-skin-cancer-molecularpathways-involved-as-targets-f, , ,"},{"key":"ref=88","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0090-6980(00)00089-7","volume":"62","author":"Wilgus T.A.","year":"2000","unstructured":"Wilgus TA, Ross MS, Parrett ML, Oberyszyn TM. Prostaglandins Other Lipid, Topical application of a selective cyclooxygenase inhibitor suppresses UVB mediated cutaneous inflammation.,, 2000, 62,, 367-384,","journal-title":"Prostaglandins Other Lipid"},{"key":"ref=89","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1093\/jnci\/djq442","volume":"102","author":"Elmets C.A.","year":"2010","unstructured":"Elmets CA, Viner JL, Pentland AP, Cantrell W, Lin HY, Bailey H, Kang S, Linden KG, Heffernan M, Duvic M, Richmond E, Elewski BE, Umar A, Bell W, Gordon GB. J Natl Cancer Inst, Chemoprevention of nonmelanoma skin cancer with celecoxib: A randomized, double-blind, placebo-controlled trial.,, 2010, 102,, 1835-1844,","journal-title":"J Natl Cancer Inst"},{"key":"ref=90","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ijc.24749","volume":"126","author":"Wulff B.C.","year":"2010","unstructured":"Wulff BC, Thomas-Ahner JM, Schick JS, Oberyszyn TM. Int J Cancer, Celecoxib reduces the effects of acute and chronic UVB exposure in mice treated with therapeutically relevant immunosupresive drugs.,, 2010, 126,, 11-18,","journal-title":"Int J Cancer"},{"key":"ref=91","first-page":"119","volume":"28","author":"Karagece Yal\u00e7in U.","year":"2012","unstructured":"Karagece Yal\u00e7in U, Se\u00e7k\u0131n S. Turk Patoloji Derg, The expression of p53 and cox-2 in basal cell csarcinoma, squamous cell carcinoma and actinic keratosis cases.,, 2012, 28,, 119-127,","journal-title":"Turk Patoloji Derg"},{"key":"ref=92","first-page":"547","volume":"19","author":"Bundscherer A.","year":"2008","unstructured":"Bundscherer A, Hafner C, Maisch T, Becker B, Landthaler M, Vogt T. Oncol Rep, Antiproliferative and proapoptotic effect of rapamycin and celecoxib in malignant melanoma cell lines.,, 2008, 19,, 547-553,","journal-title":"Oncol Rep"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/cncr.24902","volume":"116","author":"Bhatt R.S.","year":"2010","unstructured":"Bhatt RS, Merchan J, Parker R, Wu HK, Zhang L, Seery V, Heymach JV, Atkins MB, McDermott D, Sukhatme VP. Cancer, A phase 2 pilot trial of low-dose, continuos infusion, or \u201cmetronomic\u201d paclitaxel and oral celecoxib in patients with metastatic melanoma.,, 2010, 116,, 1751-1756,","journal-title":"Cancer"},{"key":"ref=94","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1017\/S0022215109004617","volume":"123","author":"Fegn L.","year":"2009","unstructured":"Fegn L, Wang Z. J Laryngol Otol, Topical chemoprevention of skin cancer in mice, using combined inhibitors of 5-lipoxygenase and ciclo-oxygenase-2.,, 2009, 123,, 880-884,","journal-title":"J Laryngol Otol"},{"key":"ref=95","first-page":"20","volume":"3","author":"Amini S.","year":"2010","unstructured":"Amini S, Viera MH, Valins W, Berman B. J Clin Aesthet Dermatol, Nonsurgical innovations in the treatment of nonmelanoma skin cancer.,, 2010, 3,, 20-34,","journal-title":"J Clin Aesthet Dermatol"},{"key":"ref=96","first-page":"476","volume":"41","author":"Clarke P.","year":"2012","unstructured":"Clarke P. Aust Fam Physician, Nonmelanoma skin cancers \u2013 treatment options.,, 2012, 41,, 476-480,","journal-title":"Aust Fam Physician"},{"key":"ref=97","author":"Feng X.","year":"","unstructured":"Feng X, Vyas D, Guan B. Novel Target Therapy and Immunotherapy for Skin Cancer., , US Pharm., 2012, 37(11) Suppl., 7-11.,","journal-title":"Novel Target Therapy and Immunotherapy for Skin Cancer"},{"key":"ref=98","doi-asserted-by":"crossref","first-page":"7386","DOI":"10.1158\/0008-5472.CAN-04-1640","volume":"64","author":"Zanon M.","year":"2004","unstructured":"Zanon M, Piris A, Bersani I, Vegetti C, Molla A, Scarito A, Anichini A. Cancer Res, Apoptosis protease activator protein-1 expression is dispensable for response of human cells to distinct proapoptotic agents.,, 2004, 64,, 7386-7394,","journal-title":"Cancer Res"},{"key":"ref=99","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2014.11.001","volume":"357","author":"Sim\u00f5es M.C.F.","year":"2015","unstructured":"Sim\u00f5es MCF, Sousa JJS, Pais AACC. Cancer Lett, Skin cancer and new treatment perspectives: A review.,, 2015, 357,, 8-42,","journal-title":"Cancer Lett"},{"key":"ref=100","first-page":"49","volume":"6","author":"Chakraborty R.","year":"2013","unstructured":"Chakraborty R, Wieland CN, Comfere NI. Pharm Pers Med, Molecular targeted therapies in metastatic melanoma.,, 2013, 6,, 49-56,","journal-title":"Pharm Pers Med"},{"key":"ref=101","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1524-4725.2011.02038.x","volume":"37","author":"Khan M.H.","year":"2011","unstructured":"Khan MH, Alam M, Yoo S. Dermatol Surg, Epidermal growth factor receptor inhibitors in the treatment of nonmelanoma skin cancers.,, 2011, 37,, 1199-1209,","journal-title":"Dermatol Surg"},{"key":"ref=102","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.ijrobp.2012.09.030","volume":"85","author":"Heath C.H.","year":"2013","unstructured":"Heath CH, Deep NL. Int J Radiat Oncol Biol Phys, Nabell, l.; Carroll, W.R.; Desmond, R.; Clemons, L. Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma.,, 2013, 85,, 1275-1281,","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref=103","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.clindermatol.2013.08.020","volume":"31","author":"Bahner J.D.","year":"2013","unstructured":"Bahner JD, Bordeaux JS. Clin Dermatol, Non-melanoma skin cancers: photodynamic therapy, cryotherapy, 5-fluorouracil, imiquimod, diclofenac, or what? Facts and controversies.,, 2013, 31,, 792-798,","journal-title":"Clin Dermatol"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.critrevonc.2013.06.002","volume":"88","author":"Mandala M.","year":"2013","unstructured":"Mandala M, Massi D, De Giorgi V. Crit Rev Oncol Hematol, Cutaneous toxicities of BRAF inhibitors: clinical and pathological challenges and call to action.,, 2013, 88,, 318-337,","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref=105","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.pdpdt.2013.05.006","volume":"10","author":"Kawczyk-Krupka A.","year":"2013","unstructured":"Kawczyk-Krupka A, Bugaj AM, Latos W, Zaremba K, Sieron A. Photodiagn Photodyn Ther, Photodynamic therapy in treatment of cutaneous and choroidal melanoma.,, 2013, 10,, 503-509,","journal-title":"Photodiagn Photodyn Ther"},{"key":"ref=106","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1600-0625.2012.01516.x","volume":"21","author":"Rodust P.M.","year":"2012","unstructured":"Rodust PM, Fecker LF, Stockfleth E, Eberle J. Exp Dermatol, Activation of mithocondrial apoptosis pathway in cutaneous squamous cell carcinoma cells by di- clofenac\/hyaluronic acid is related to upregulation of Bad as well as downregulation of Mcl-1 and Bcl-w.,, 2012, 21,, 520-525,","journal-title":"Exp Dermatol"},{"key":"ref=107","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.mad.2008.09.003","volume":"129","author":"Kim S.R.","year":"2008","unstructured":"Kim SR, Park JH, Lee ME, Park JS, Park SC, Han JA. Mech Ageing Dev, Selective COX-2 inhibitors modulate cellular senescence in human dermal fibroblast in a catalytic activity-independent manner.,, 2008, 129,, 706-713,","journal-title":"Mech Ageing Dev"},{"key":"ref=108","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2011.12.018","volume":"678","author":"Li F.","year":"2012","unstructured":"Li F, Liu S, Ouyang Y, Fan C, Wang T, Zhang C, Zeng B, Chai Y, Wang X. Eur J Pharmacol, Effect of celecoxib on proliferation, collagen expresion, ERK1\/2 and SMAD2\/3 phosphorylation in NIH\/3T3 fibroblasts.,, 2012, 678,, 1-5,","journal-title":"Eur J Pharmacol"},{"key":"ref=109","doi-asserted-by":"crossref","first-page":"e56212","DOI":"10.1371\/journal.pone.0056212","volume":"8","author":"DeCicco-Skinner K.L.","year":"2013","unstructured":"DeCicco-Skinner KL, Nolan SJ, Deshpande MM, Trovato EL, Dempsey TA, Wiest JS. PLoS One, Altered prostanoid signaling contributes to increased skin tumorigenesis in Tpl2 knockout mice.,, 2013, 8,, e56212-,","journal-title":"PLoS One"},{"key":"ref=110","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.molonc.2013.11.005","volume":"8","author":"Escuin-Ordinas H.","year":"2014","unstructured":"Escuin-Ordinas H, Atefi M, Fu Y, Cass A, Ng C, Huang RR, Yashar S, Comin-Anduix B, Avramis E, Cochran AJ, Marais R, Lo RS, Graeber TG, Herschman HR, Ribas A. Mol Oncol, COX-2 inhibition prevents the apparence of cutaneous squamous cell carcinoma acelerated by BRAF inhibitors.,, 2014, 8,, 250-260,","journal-title":"Mol Oncol"},{"key":"ref=111","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1158\/1940-6207.CAPR-09-0200","volume":"3","author":"Tang J.Y.","year":"2010","unstructured":"Tang JY, Aszterbaum M, Athar M, Barsanti F, Cappola C, Estevez N, Hebert J, Hwang J, Khaimskiy Y, Kim A, Lu Y, So PL, Tang X, Kohn MA, McCulloch CE, Kopelovich L, Bickers DR, Epstein EH. Cancer Prev Res (Phila), Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1*(+\/\u2212) humans and mice.,, 2010, 3,, 25-34,","journal-title":"Cancer Prev Res (Phila)"},{"key":"ref=112","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/mc.10142","volume":"38","author":"Wilgus T.A.","year":"2003","unstructured":"Wilgus TA, Koki AT, Zweifel BS, Rubal PA, Oberyszyn TM. Mol Carcinog, Chemotherapeutic efficacy of topical celecoxib in a murine model of Ultraviolet Light B-Induced skin cancer.,, 2003, 38,, 33-39,","journal-title":"Mol Carcinog"},{"key":"ref=113","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1093\/carcin\/20.10.1939","volume":"20","author":"Pentland A.P.","year":"1999","unstructured":"Pentland AP, Schoggins JW, Scott GA, Khan KN, Han R. Carcinogenesis, Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition.,, 1999, 20,, 1939-1944,","journal-title":"Carcinogenesis"},{"key":"ref=114","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/carcin\/bgg046","volume":"24","author":"Fischer S.M.","year":"2003","unstructured":"Fischer SM, Conti CJ, Viner J, Aldaz CM, Lubet RA. Carcinogenesis, Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice.,, 2003, 24,, 945-952,","journal-title":"Carcinogenesis"},{"key":"ref=115","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3109\/10717544.2012.724472","volume":"19","author":"Bragagni M.","year":"2012","unstructured":"Bragagni M, Mennini N, Maestrelli F, Cirri M, Mura P. Drug Deliv, Comparative study of liposomes, transfersomes and ethosomes as carriers for improving topical delivery of celecoxib.,, 2012, 19,, 345-361,","journal-title":"Drug Deliv"},{"key":"ref=116","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejpb.2009.04.016","volume":"73","author":"Simonetti L.D.","year":"2009","unstructured":"Simonetti LD, Gelfuso GM, Barbosa JC, Lopez RF. Eur J Pharm Biopharm, Assesment of the percutaneous penetration of cisplastin: The effect of monoolein and the drug skin penetration pathway.,, 2009, 73,, 90-94,","journal-title":"Eur J Pharm Biopharm"},{"key":"ref=117","first-page":"1435","volume":"58","author":"Tennenbaum T.","year":"1998","unstructured":"Tennenbaum T, Lowry D, Darwiche N, Morgan DL, Gartsbein M, Hansen L, De Luca LM, Hennings H, Yuspa SH. Cancer Res, Topical retinoic acid reduces skin papilloma formation but resistant papillomas are at high risk for malignant conversion.,, 1998, 58,, 1435-1443,","journal-title":"Cancer Res"},{"key":"ref=118","first-page":"1252","volume":"38","author":"Chun K.S.","year":"2006","unstructured":"Chun KS, Kundu JK, Park KK, Chung WY, Surh YJ. Cancer Res Treat, Inhibition of phorbol ester\u2013induced mouse skin tumor promotion and COX\u20132 expression by celecoxib: C\/EPB as a potencial molecular target.,, 2006, 38,, 1252-1258,","journal-title":"Cancer Res Treat"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ijpharm.2012.06.044","volume":"436","author":"Ochalek M.","year":"2012","unstructured":"Ochalek M, Podhaisky H, Ruettinger HH, Neubert RH, Wohlrab J. Int J Pharm, SC lipid model membranes designed for studying impact of ceramides species on drug diffusion and permeation, part iii: influence of penetration enhancer on diffusion and permeation of models drugs.,, 2012, 436,, 206-213,","journal-title":"Int J Pharm"},{"key":"ref=120","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1016\/j.biomaterials.2010.03.010","volume":"31","author":"Patlolla R.R.","year":"2010","unstructured":"Patlolla RR, Desai PR, Belay K, Singh MS. Biomaterials, Translocation of cell penetrating peptide engrafted nanoparticles across skin layers.,, 2010, 31,, 5598-5607,","journal-title":"Biomaterials"},{"key":"ref=121","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijpharm.2006.02.006","volume":"314","author":"Ventura C.A.","year":"2006","unstructured":"Ventura CA, Tommasini S, Falcone A, Giannone I, Paolino D, Sdrafkakis V, Mondello MR, Puglisi G. Int J Pharm, Influence of modified cyclodextrins on solubility and percutaneous absorption of celecoxib through human skin.,, 2006, 314,, 37-45,","journal-title":"Int J Pharm"},{"key":"ref=122","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1016\/j.bbamem.2011.08.012","volume":"1808","author":"Engelbrecht T.N.","year":"2011","unstructured":"Engelbrecht TN, Schroeter A, Hauss T, Neubert RH. Biochim Biophys Acta, Lipophilic penetration enhancers and their impact to the bilayer structure of stratum corneum lipid model membranes: Neutron diffraction studies based on the example Oleic Acid.,, 2011, 1808,, 2798-2806,","journal-title":"Biochim Biophys Acta"},{"key":"ref=123","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jconrel.2009.04.023","volume":"138","author":"M\u00e9lot M.","year":"2009","unstructured":"M\u00e9lot M, Pudney PD, Williamson AM, Caspers PJ, Van Der Pol A, Puppels GJ. J Control Release, Studying the effectiveness of penetration enhancers to deliver retinol through the stratum corneum by in vivo confocal raman spectroscopy.,, 2009, 138,, 32-39,","journal-title":"J Control Release"},{"key":"ref=124","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ijpharm.2006.08.021","volume":"329","author":"Herai H.","year":"2007","unstructured":"Herai H, Gratieri T, Thomazine JA, Bentley MV, Lopez RF. Int J Pharm, Doxorubicin skin penetration from monolein\u2013containing propylene glycol formulations.,, 2007, 329,, 88-93,","journal-title":"Int J Pharm"},{"key":"ref=125","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/S0169-409X(02)00116-3","volume":"54","author":"Kreilgaard M.","year":"2002","unstructured":"Kreilgaard M. Adv Drug Deliv Rev, Influence of microemulsions on cutaneous drug delivery.,, 2002, 54,, S77-S98,","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=126","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s00403-011-1166-4","volume":"303","author":"Pierre M.B.","year":"2011","unstructured":"Pierre MB, Dos Santos Miranda Costa I. Arch Dermatol Res, Liposomal systems as drug delivery vehicles for dermal and transdermal applications.,, 2011, 303,, 607-621,","journal-title":"Arch Dermatol Res"},{"key":"ref=127","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ijpharm.2012.01.045","volume":"427","author":"Srisuk P.","year":"2012","unstructured":"Srisuk P, Thongnopnua P, Raktanonchai U, Kanokpanont S. Int J Pharm, Physico-chemical characteristics of methotrexate-entrapped oleic acid- containing deformable liposomes for in vitro transepidermal delivery targeting treatment.,, 2012, 427,, 426-434,","journal-title":"Int J Pharm"},{"key":"ref=128","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1021\/mp9002442","volume":"7","author":"Tan A.","year":"2010","unstructured":"Tan A, Simovic S, Davey AK, Rades T, Boyd BJ, Prestidge CA. Mol Pharm, Silica nanoparticles to control the lipase-mediated digestion of lipid- based oral delivery systems.,, 2010, 7,, 522-532,","journal-title":"Mol Pharm"},{"key":"ref=129","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/jbm.a.31835","volume":"87","author":"McCarron P.A.","year":"2008","unstructured":"McCarron PA, Marouf WM, Donnelly RF, Scott C. J Biomed Mater Res, Enhanced surface attachment of protein-type targeting ligands to poly(lactide-co-glycolide) nanoparticles using variable expression of polimeric acid functionality.,, 2008, 87,, 873-884,","journal-title":"J Biomed Mater Res"},{"key":"ref=130","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4161\/derm.1.4.9501","volume":"1","author":"Schneider M.","year":"2009","unstructured":"Schneider M, Stracke F, Hansen S, Schaefer UF. Dermatoendocrinol, Nanoparticles and their interactions with the dermal barrier.,, 2009, 1,, 197-206,","journal-title":"Dermatoendocrinol"},{"key":"ref=131","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jconrel.2010.10.005","volume":"149","author":"Batheja P.","year":"2011","unstructured":"Batheja P, Sheihet L, Kohn J, Singer AJ, Michniak-Kohn B. J Control Release, Topical drug delivery by a polimeric nanosphere gel: formulation optimization and in vitro and in vivo skin distribution studies.,, 2011, 149,, 159-167,","journal-title":"J Control Release"},{"key":"ref=132","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0169-409X(01)00105-3","volume":"47","author":"Mehnert W.","year":"2001","unstructured":"Mehnert W, M\u00e4der K. Adv Drug Deliv Rev, Solid lipid nanoparticles production, characterization and applications.,, 2001, 47,, 165-196,","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=133","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijpharm.2013.01.024","volume":"444","author":"Hussain Z.","year":"2013","unstructured":"Hussain Z, Katas H, Mohd Amin MC, Kumolosasi E, Buang F, Sahudin S. Int J Pharm, Self-assembled polymeric nanoparticles for percutaneous co-delivery of hydrocortisone\/hydroxytyrosol: An ex vivo and in vivo study using an NC\/Nga mouse model.,, 2013, 444,, 109-119,","journal-title":"Int J Pharm"},{"key":"ref=134","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1208\/s12249-014-0171-2","volume":"15","author":"Estracanholli E.A.","year":"2014","unstructured":"Estracanholli EA, Pra\u00e7a FSG, Cintra AB, Pierre MBR, Lara MG. AAPS PharmSciTech, Liquid crystalline systems for transdermal delivery of celecoxib: in vitro drug release and skin permeation studies.,, 2014, 15,, 1468-1475,","journal-title":"AAPS PharmSciTech"},{"key":"ref=135","author":"Dante M.C.L.","year":"","unstructured":"Dante MCL, Borgheti-Cardoso LN, Fantini MCA, Pra\u00e7a FSG, Medina WSG, Pierre MBR, Lara MG. , , Liquid crystalline systems based on glyceryl monooleate and penetration enhancers for skin delivery of celecoxib: characterization, In Vitro drug release, and in vivo studies. J. Pharm. Sci., 2017, pii: S0022- 3549(17), 30778-30785,"}],"container-title":["Current Cancer Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/161688","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T01:20:10Z","timestamp":1751592010000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/161688\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,13]]},"references-count":135,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12,13]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1568009618666180430125201","relation":{},"ISSN":["1568-0096"],"issn-type":[{"value":"1568-0096","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12,13]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2017-09-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-31","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-03-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}